

# Performance of CAD4TB Artificial Intelligence Technology in TB Screening Programs Among the Adult Population in South Africa and Lesotho

Nonhlanhla Nzimande

Human Sciences Research Council/Sweetwaters Pietermaritzburg/South Africa

27 September 2024

*Keelin Murphy<sup>3</sup>, Klaus Reither<sup>4, 5</sup>, Shannon Bosman<sup>2</sup>, Irene Ayakaka<sup>6</sup>, Tracy R. Glass<sup>4, 5</sup>, Fiona Vanobberghen<sup>4, 5</sup> & Jabulani Ncayiyana<sup>1</sup>*


<sup>1</sup>Division of Public Health Medicine, School of Nursing and Public Health, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. <sup>2</sup>Center for Community Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa. <sup>3</sup>Radboud University Medical Center, Nijmegen, The Netherlands. <sup>4</sup>Swiss Tropical and Public Health Institute, Allschwil, Switzerland. <sup>5</sup>University of Basel, Basel, Switzerland. <sup>6</sup>Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

NTP Lesotho provided data from the National Tuberculosis Prevalence Survey in Lesotho based on a data-sharing agreement

# Introduction

- TB is still a significant public health concern:
  - ❑ 10.6 million developed TB in 2022
  - ❑ 1.3 million TB-related deaths
  - ❑ Over 4 million undiagnosed cases
- Low and middle-income countries most vulnerable
- Urgency to reduce diagnostic gap
- WHO TPP recommendation of triage tests (90% sensitivity & 70% specificity)
- In 2021, WHO endorsed the use of AI products for chest X-rays in TB screening

## CAD4TB




CAD score: 89.84

*TB Triage+ study*



# Rationale

## a) WHO endorsement of Computer-Aided Detection (CAD)



### 3.2 Use of computer-aided detection software for automated reading of digital chest radiographs

10. Among individuals aged 15 years and older in populations in which TB screening is recommended, computer-aided detection software programmes may be used in place of human readers for interpreting digital chest X-rays for screening and triage for TB disease (new recommendation: conditional recommendation, low certainty of evidence).

## Retrospective case-control accuracy study


Two parent studies

☐ TB Triage+ accuracy study


☐ Lesotho TB National Prevalence study

- Aim
- Objectives


## b) Focus on African Populations



## d) Effects of various parameters on CAD



## c) Threshold-specific CAD analysis



	TB negative 6 236, (95.59%) N, (%)	TB positive 288, (4.41%) N, (%)	Total (6 524) N, (%)
Age (yrs.) Mean, SD	49, 18.63	48, 17.61	49, 18.59
<b>Age group</b>			
15-19	306 (4.91)	7 (2.43)	313 (4.80)
20-29	797 (12.78)	44 (15.28)	841 (12.89)
30-39	1 005 (16.12)	59 (20.49)	1 064 (16.31)
40-49	959 (15.38)	50 (17.36)	1 009 (15.47)
50-59	1 096 (17.58)	40 (13.89)	1 136 (17.41)
60-69	1 104 (17.70)	47 (16.32)	1 151 (17.64)
70-79	664 (10.65)	32 (11.11)	696 (10.67)
80+	305 (4.89)	9 (3.12)	314 (4.81)
<b>Sex</b>			
Male	3 139 (50.34)	191 (66.32)	3 330 (51.04)
Female	3 097 (49.66)	97 (33.68)	3 194 (48.96)
<b>Country</b>			
South Africa	477 (7.65)	65 (22.57)	542 (8.31)
Lesotho	5 759 (92.35)	223 (77.43)	5 982 (91.69)
<b>Study name</b>			
TB Triage+	1 086 (17.42)	134 (46.53)	1 220 (18.70)
**LPS	5 150 (82.58)	154 (53.47)	5 304 (81.30)
<b>HIV status</b>			
HIV negative	4 075 (65.35)	143 (49.65)	4 218 (64.65)
HIV positive	1 673 (26.83)	122 (42.36)	1 795 (27.51)
Unknown	488 (7.83)	23 (7.99)	511 (7.83)
<b>*Hardware</b>			
H1	609 (9.77)	69 (23.96)	678 (10.39)
H2	477 (7.65)	65 (22.57)	542 (8.31)
H3	1 842 (29.54)	48 (16.67)	1 890 (28.97)
H4	2 436 (39.06)	89 (30.90)	2 525 (38.70)
H5	872 (13.98)	17 (5.90)	889 (13.63)
<b>Prev TB</b>			
No	5 146 (82.52)	230 (79.86)	5 376 (82.40)
Yes	1 090 (17.48)	58 (20.14)	1 148 (17.60)
<b>CAD4TB</b>			
*v6 -median, IQR	52.19, 17.84	76.47, 19.28	53.26, 18.59
*v7- median, IQR	20.03, 22.09	61.70, 27.37	21.87, 23.93

# Participants' characteristics

## \*\*Hardware (hardware used in image acquisition)

H1= Canon Inc.: CXDI Control Software NE;

H2=Vieworks Co.,Ltd: FXRD-1717VA;


H3=Samsung Electronics: SDR-AGR40CW:  
SMD4343WS;

H4=Samsung Electronics: DGR-RN2N22/WR:  
SMD4343WS;


H5=SEDECAL DR: Copyright(C) SEDECAL Corp

# Results

CAD4TB v6 & v7 ROC graph



## Threshold independent analysis



## Threshold dependent analysis

v6- min 90% sens, 54% spec


v7- min 90% sens, 65% spec

v6- min 70% spec, 83 sens


v7- min 70% spec, 88% sens




CAD4TB v6 by age groups




CAD4TB v7 by age groups





CAD4TB v6 by prev\_tb



CAD4TB v7 by prev\_tb



**Notable performance differences between age groups and previous history of TB**



## Notable performance differences between hardware used in image acquisition

### \*\*Hardware (hardware used in image acquisition)









H1= Canon Inc.: CXDI Control Software NE;

H2=Vieworks Co.,Ltd: FXRD-1717VA;

H3=Samsung Electronics: SDR-AGR40CW: SMD4343WS;

H4=Samsung Electronics: DGR-RN2N22/WR: SMD4343WS;

H5=SEDECAL DR: Copyright(C) SEDECAL Corp



**No performance difference between the subgroups**



# Conclusion

CAD4TB - effective TB screening tool in high TB-burdened and resource-constrained settings

## 1. Performance (area under ROC)

- Version 7 shows improved performance
- Better in younger groups, better in groups with no history of TB
- Variability noted across different hardware (significant?)

## 2. Thresholds

The threshold needed for a particular level of sensitivity/specificity is very different for v6 and v7

3. Both versions did not meet the **WHO TPP –trriage test** (attributable to variability in analysed data?)

# Acknowledgements



UNIVERSITY OF  
KWAZULU-NATAL™  
INYUVESI  
YAKWAZULU-NATALI



**HSRC**  
Human Sciences  
Research Council

## Swiss TPH

Swiss Tropical and Public Health Institute



## SOLIDAR MED

## Radboudumc



WORLD CONGRESS OF EPIDEMIOLOGY 2024